
G1 THERAPEUTICSCS INC
Action · US3621LQ1099 · GTHX · A2DR0J (XNAS)
Pas de cours
n/a
Performance
Jour | Semaine | Mois | 3 mois | 6 mois | 1 an | 5 ans |
---|---|---|---|---|---|---|
- | - | - | - | 0,00 % | 140,74 % | -64,02 % |
Profil de l'entreprise pour G1 THERAPEUTICSCS INC Action
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Fonds investis
Les fonds suivants ont investi dans : G1 THERAPEUTICSCS INC investi :
Fonds | Vol. en millions 20,33 | Part (%) 0,05 % |
Données de l'entreprise
Nom G1 THERAPEUTICSCS INC
Société G1 Therapeutics, Inc.
Symbole GTHX
Site web
https://www.g1therapeutics.com
Marché d'origine
NASDAQ

WKN A2DR0J
ISIN US3621LQ1099
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Mr. John E. Bailey Jr.
Capitalisation boursière 378 Mio
Pays États-Unis d'Amérique
Devise USD
Employés 0,1 T
Adresse 700 Park Offices Drive, 27709 Research Triangle Park
Date d'introduction en bourse 2017-05-17
Symboles boursiers
Nom | Symbole |
---|---|
Frankfurt | G1H.F |
NASDAQ | GTHX |
Autres actions
Les investisseurs qui détiennent G1 THERAPEUTICSCS INC ont également les actions suivantes dans leur portefeuille :
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles.
Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.